Weight Management

GLP-1 hair loss: what Mounjaro and Wegovy users need to know

13 min read
A hairbrush on a bright bathroom counter in soft morning light

Key points

  • A large study published in The BMJ on 22 July 2026 found people taking GLP-1 medicines had a higher rate of hair loss than people taking other diabetes medicines.
  • The absolute risk is small: roughly 7 cases per 1,000 people per year on a GLP-1, compared with 4 to 5 per 1,000 on the comparison medicines.
  • The hair loss seen was non-scarring, which means the follicle survives and hair can regrow.
  • Rapid weight loss, not the medicine itself, is the most likely trigger — so protein intake, iron levels and the pace of weight loss are the things worth fixing first.
  • Shedding that starts two to four months after a big change in weight usually settles within six to nine months.

If you are taking Mounjaro, Wegovy or Ozempic and you have noticed more hair than usual in the shower drain, you are not imagining it — and you are not alone. GLP-1 hair loss has moved from patient forums into the medical literature, and on 22 July 2026 researchers published the largest study so far linking these medicines to an increased risk of hair shedding.

Here is what the research actually says, why it happens, and what a pharmacist would suggest you do about it.

What the new research found

Researchers at the University of Pennsylvania used anonymised patient records from the Penn Medicine health system covering January 2019 to September 2024. They compared adults with type 2 diabetes who started a GLP-1 receptor agonist against adults who started a different class of diabetes medicine, using a method called target trial emulation — a way of squeezing something close to a clinical trial out of real-world records.

Comparison Group sizes Hair loss rate Relative increase
GLP-1 vs SGLT-2 inhibitors 12,004 vs 15,221 6.91 vs 5.04 per 1,000 person-years 37% higher
GLP-1 vs DPP-4 inhibitors 11,964 vs 11,233 6.53 vs 3.89 per 1,000 person-years 68% higher

Those percentages sound alarming until you look at the underlying numbers. A rate of 6.91 per 1,000 person-years means that if 1,000 people took a GLP-1 for a year, about seven of them would have hair loss recorded by a doctor — against about five in the comparison group. It is a real difference, but it is a small one, and the great majority of people on these medicines will not experience it.

When the researchers looked specifically at non-scarring alopecia — the type where the hair follicle stays intact and hair can grow back — the signal was stronger, at 53% and 72% higher respectively. That is actually reassuring: it points towards temporary shedding rather than permanent loss.

Two caveats worth knowing

This study was carried out in adults with type 2 diabetes, not in people using GLP-1 medicines purely for weight loss. People losing weight faster, or eating less, may not behave the same way.

The authors were also clear about the limits of their data. They could not assess the severity, extent, duration or reversibility of the hair loss, and they could not rule out other unmeasured factors.

How many hair loss reports have regulators received?

Regulators collect suspected side effects through voluntary reporting schemes. In the UK, the Medicines and Healthcare products Regulatory Agency has recorded, through its Yellow Card scheme:

  • Tirzepatide (Mounjaro): 399 reports of hair loss in 2026, following 541 in 2025.
  • Semaglutide (Wegovy, Ozempic): 148 reports in 2026, following 164 in 2025.

In the United States, the Food and Drug Administration has been made aware of the association and is evaluating it as a potential safety signal.

Two things to keep in mind when reading those figures. A report is a suspicion, not proof that the medicine caused the problem. And reporting schemes capture only a fraction of what actually happens — the true numbers are certainly higher, and reporting rises whenever a side effect gets media coverage. The higher count for tirzepatide also partly reflects how many more people are taking it.

Hair shedding has been one of the most-discussed effects in patient communities for a couple of years now, well ahead of the formal evidence. The pattern people describe is fairly consistent: shedding starts a couple of months after a period of rapid weight loss, comes out evenly across the whole scalp rather than in patches, and settles down over the following months.

Why do GLP-1 medicines cause hair loss?

The most likely explanation is not the medicine acting on your hair directly. It is telogen effluvium — a well-recognised reaction to physical stress that has been documented for decades after childbirth, surgery, serious illness, crash dieting and bariatric surgery.

Hair grows in cycles. At any moment most of your hair is in an active growing phase and around one in ten is in a resting phase before it falls out. A significant physical stressor pushes far more follicles into that resting phase at once. They all sit there for roughly two to three months, then shed together — which is why the shedding shows up months after the event that caused it, long after you have stopped connecting the two.

With GLP-1 medicines, several things stack up at the same time:

  • Rapid weight loss is itself an established trigger of hair shedding, regardless of how the weight came off.
  • Reduced appetite means reduced intake. These medicines work by making you eat less, and it is easy to fall short on protein without noticing.
  • Micronutrient shortfalls — particularly iron, zinc and vitamin B12 — interfere with the hair growth cycle. Eating less overall makes these more likely.
  • Hormonal and thyroid changes that come with significant weight loss may also play a part, though the researchers were explicit that more work is needed here.

The practical upshot is important: if the trigger is how you are losing weight rather than the drug itself, then it is something you can influence — without stopping a medicine that is working for you.

The typical timeline

Months 1–2: weight starts coming off; no hair changes yet.

Months 2–4: shedding becomes noticeable — more hair on the pillow, in the brush and in the shower.

Months 4–6: shedding peaks, then slows as the weight loss rate levels off.

Months 6–12: regrowth. New hair often appears as short, fine "baby hairs" around the hairline first.

Where hair loss sits among GLP-1 side effects

Hair loss is not among the common side effects of GLP-1 medicines, and it does not currently appear in the licensed product information for most of them. For context, here is how it compares with the effects people actually experience most often.

Effect How common Usually settles
Nausea Very common (more than 1 in 10) 4–8 weeks, and after each dose increase
Constipation or diarrhoea Very common Ongoing, but manageable
Reduced appetite, feeling full quickly Very common Expected effect, not a side effect
Fatigue Common (up to 1 in 10) Often improves with better intake
Muscle loss alongside fat loss Common without resistance training Preventable with protein and strength work
Hair shedding Uncommon — around 7 per 1,000 per year 3–6 months once weight stabilises

What you can do about GLP-1 hair loss

Get your protein up first

This is the single highest-value change. Hair is made almost entirely of keratin, a protein, and your body treats hair as non-essential when protein is scarce. Aim for roughly 1.2 to 1.6 grams of protein per kilogram of body weight per day. For someone weighing 90 kg, that is around 110 g to 145 g daily — considerably more than most people manage when their appetite has been switched off.

If solid food is difficult, a protein shake, Greek yoghurt or cottage cheese will often go down when a chicken breast will not.

Check your iron rather than guessing

Low iron is one of the most common reversible causes of hair shedding, especially in women who are still menstruating. But taking iron you do not need is not harmless — it causes constipation, which is already a problem on GLP-1 medicines, and excess iron accumulates in the body. Ask your GP for a full blood count and a ferritin level rather than starting a supplement blindly.

Slow down if the weight is coming off very fast

Losing more than about 1 kg per week over a sustained period increases the odds of shedding. If your hair matters to you and you are dropping weight rapidly, a conversation with your prescriber about holding your current dose rather than escalating is a reasonable one to have.

Be gentle with the hair you have

None of this regrows hair, but it stops you losing more mechanically: skip tight ponytails and buns, go easy on heat styling and chemical treatments, use a wide-tooth comb on wet hair, and do not over-wash. Washing does not cause shedding — it just collects hair that had already let go.

Not sure whether this is normal shedding or something else?

Our pharmacists can talk through what you are taking, what you are eating and whether anything needs checking — no appointment needed.

Do supplements help?

Honest answer: they help if you are short of something, and they do very little if you are not. That is a less satisfying answer than the supplement aisle suggests, but it is the accurate one.

Biotin is the vitamin most associated with hair. True biotin deficiency is genuinely rare in people eating a normal diet, and where it exists, supplementing corrects the hair problem. Where it does not exist, the evidence for benefit is weak. That said, appetite suppression makes low intake more plausible than usual, biotin is inexpensive and it is well tolerated, so it is a reasonable thing to try alongside the changes above — not instead of them.

Sons Biotin Hair Vitamin 30 Capsules Available at Healthwave Sons Biotin Hair Vitamin 30 CapsulesOne capsule daily; suitable for men and women €9.95In stock View product

Tell your doctor if you take biotin

High-dose biotin interferes with several common laboratory tests, including thyroid function tests and the troponin test used to diagnose a heart attack. It can push results high or low enough to cause a real misdiagnosis. Always mention biotin before blood tests, and stop it a few days beforehand if your doctor advises.

This matters here in particular, because thyroid problems are one of the things worth ruling out when someone has unexplained hair loss.

A general multivitamin covering zinc, B12 and vitamin D is a sensible baseline while you are eating substantially less than usual. Iron is the exception — get it tested first.

Does minoxidil help with GLP-1 hair loss?

This needs a careful answer, because the honest one is more useful than the marketing one.

Minoxidil is licensed for hereditary pattern hair loss — androgenetic alopecia, the gradual thinning at the crown and temples in men, or the widening parting in women. It is not licensed for telogen effluvium, the diffuse shedding described above, and telogen effluvium usually resolves without any treatment once the trigger passes.

So minoxidil is not the first thing to reach for if your hair started shedding two months into a GLP-1.

Where it genuinely earns its place is this: a great many people already have some degree of pattern hair loss in the background, quietly progressing for years. A telogen effluvium episode strips away the padding and makes that underlying thinning suddenly obvious. The shedding recovers — but the pattern loss it revealed does not, and carries on. If your parting has widened, or your temples have receded, and it has not returned to normal six to nine months after your weight stabilised, that is pattern hair loss and minoxidil is the treatment with the best evidence behind it.

Two things to know before you start. Minoxidil causes a temporary increase in shedding in the first few weeks as resting hairs are pushed out to make way for new growth — unnerving if you are not expecting it. And it only works while you keep using it; stopping means the gains are gradually lost. Give it at least four months before judging it.

Extra Strength 5% For Men & Women Hair Loss Treatment 3 X 60 Ml Available at Healthwave Regaine Men & Women Extra Strength 5% Cutaneous Solution 60ml x 3 months5% minoxidil solution, suitable for men and women aged 18-65 €86.95In stock View product Regaine Women Extra Strength 5% w/w Foam 2 x 60g Available at Healthwave Regaine Women Extra Strength 5% w/w Foam 2 x 60gOnce-daily foam, formulated specifically for female pattern hair loss €51.95In stock View product Browse all hair-loss treatments

Minoxidil is not suitable in pregnancy or while breastfeeding, or if you have a scalp condition affecting the skin where it would be applied. If you are unsure whether it is right for you, ask one of our pharmacists before buying.

When to speak to a pharmacist or doctor

Get it looked at if

  • Hair is coming out in distinct round patches rather than thinning evenly — that suggests alopecia areata, which is a different condition needing different treatment.
  • Your scalp is sore, itchy, scaly, red or scarring. Scarring alopecia can cause permanent loss and needs prompt assessment.
  • Shedding is still getting worse after six months, or has not improved nine months after your weight stabilised.
  • You also have fatigue, breathlessness, cold intolerance or heavy periods — worth checking iron and thyroid function.
  • It is affecting your mood or confidence. Hair loss is not a cosmetic triviality, and the study authors specifically noted its effect on self-esteem, quality of life and whether people stick with treatment at all.

One thing not to do: stop a prescribed medicine on your own. If your GLP-1 is controlling your diabetes or delivering weight loss that matters for your health, stopping it because of hair shedding that is likely to resolve anyway is rarely the right trade. Talk to your prescriber before changing anything.

Reporting a side effect in Ireland

If you think a medicine has caused a side effect, you can report it yourself — you do not need to go through a doctor, and you do not need to be certain the medicine was responsible. These reports are how safety signals like this one get detected in the first place.

Report to the Health Products Regulatory Authority at hpra.ie. You can also tell us, and we will help you submit it.

Common questions

Does Mounjaro cause hair loss?

Hair loss is not a listed common side effect of Mounjaro, and the evidence points to rapid weight loss as the trigger rather than tirzepatide itself. The BMJ study found people on GLP-1 medicines had a higher rate of hair loss than people on other diabetes medicines — roughly seven cases per 1,000 people per year against four to five — so the risk is real but small.

Will my hair grow back?

In most cases, yes. The hair loss identified in the study was non-scarring, meaning the follicles survive. Telogen effluvium typically recovers within six to nine months once weight stabilises and nutrition improves. Regrowth is gradual, and new hair often comes in shorter and finer at first.

Is it the same with Wegovy and Ozempic?

The study looked at GLP-1 receptor agonists as a class, which includes semaglutide — the active ingredient in both Wegovy and Ozempic. UK regulators have received hair loss reports for both semaglutide and tirzepatide. The mechanism is thought to be the same in each case.

Can I use minoxidil while taking a GLP-1 medicine?

There is no known interaction between topical minoxidil and GLP-1 medicines. Whether minoxidil is the right choice depends on the type of hair loss you have — see the section above, and ask a pharmacist if you are not sure.

Should I stop my medicine if my hair is falling out?

Not without speaking to your prescriber. The shedding is usually temporary, and there are things worth trying first — protein intake, checking iron, and slowing the rate of weight loss.

Talk it through with a pharmacist

If you are on a GLP-1 and something does not feel right, we would rather you asked. Our pharmacy team is here six days a week.

Sources

  1. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. The BMJ, 22 July 2026. doi:10.1136/bmj-2026-100077.
  2. Medicines and Healthcare products Regulatory Agency (MHRA), Yellow Card suspected side effect reports for tirzepatide and semaglutide, 2025–2026.
  3. US Food and Drug Administration, FDA Adverse Event Reporting System — potential signals of serious risks.
  4. Health Products Regulatory Authority — report a side effect of a medicine for human use.
  5. News coverage: RTÉ News, “Weight loss drugs ‘linked to hair loss’ – study”, 23 July 2026.

This article is general information for people in Ireland and is not a substitute for individual medical advice. Always speak to your pharmacist, GP or prescriber about your own treatment.

Back to blog